Trial result ·
Durable responses to long-term selumetinib in Chinese pediatric NF1 patients with inoperable plexiform neurofibromas.
Written based on 1 research study on PubMed, searched on 3 Nov 2026.
What was studied
This single-center trial tested selumetinib in Chinese children with NF1-related plexiform neurofibromas. The tumors could not be removed by surgery. The trial enrolled 16 children, with a median age of 11 years. They took the drug at a set dose in 28-day cycles. Treatment went on until the disease grew or they could not tolerate it. MRI scans measured tumor response.
What they found
The response rate stayed the same at both data cut-offs. The authors describe the tumor responses as lasting. All 16 children had at least one adverse event. For 12 of 16 children, at least one event was linked to the drug. No drug-linked events of grade 3 or higher were seen. Pain and quality of life scores improved with treatment.
What it means for patients
The authors say long-term selumetinib led to lasting tumor responses. They also report lasting pain relief. They found no new safety signals. They add that known adverse events still need ongoing monitoring.
Why it is not certain yet
The abstract describes one center and 16 children. It describes no comparison group. Findings on growth and skin pigment were exploratory. They were seen in children before puberty.
The registered trial
The paper names this trial from a public trial registry. Its page shows who the trial is for, its sites and its status.
Source
Durable responses to long-term selumetinib in Chinese pediatric NF1 patients with inoperable plexiform neurofibromas.
PubMed · PMID 42394972We restate facts from the source record in our own words. The original wording belongs to its publisher.
This page is not medical advice. Talk to your doctor about your own care.
Back to Childhood cancers publications